Full articles are free to read through December 10, 2026 (IST). Subscriptions remain available.
SILVER SPRING, MD — The landscape of neurological medicine has shifted dramatically with a major regulatory breakthrough from the U.S. Food and Drug Administration. Federal regulators on Monday granted approval to Sunharbo (asundexian) 50 mg tablets, pioneering a brand-new pharmacological class known as factor XIa inhibitors. Designed to aggressively combat secondary ischemic events, this therapeutic innovation is authorized to be taken in direct combination with standard antiplatelet therapy to safely prevent recurrent strokes in adults who have recently survived mild-to-moderate non-cardioembolic ischemic strokes or high-risk transient ischemic attacks, frequently categorized by clinicians as mini-strokes.
This milestone regulatory authorization targets a primary catalyst of neurological mortality and permanent adult disability across the Western world. Clinical efficacy was rigorously validated during the expansive phase three OCEANIC-STROKE clinical trials, a massive multicenter study tracking twelve thousand three hundred and twenty-seven adult patients. Investigators demonstrated that a once-daily fifty milligram dosage of Sunharbo administered within seventy-two hours of initial symptom onset successfully drove down the relative risk of a subsequent ischemic stroke by an astonishing twenty-six percent compared to the placebo cohort over a median tracking timeline of fourteen point two months.
Clinical safety analyses indicate that while the overall rate of major bleeding events remained statistical parity between the two primary testing groups, a distinct spike in bleeding vulnerability was recorded among elderly patients older than seventy-five and across the initial ninety days of starting treatment. Gastrointestinal bleeding was identified as a notable clinical risk factor, with diarrhea emerging as the most prevalent adverse reaction among patients. Federal health experts warn that Sunharbo is strictly not indicated for stroke prevention in patients presenting with atrial fibrillation and must be temporarily withheld for at least twenty-four hours before elective surgical operations or invasive clinical procedures.
The landmark drug development, which received expedited Fast Track and Priority Review status from federal authorities, was officially awarded to New Jersey-based pharmaceutical powerhouse Bayer HealthCare Pharmaceuticals Inc. Due to specialized biochemical pathways, clinicians are advised that concurrent use with strong combination P-gp and CYP3A4 inducing medications, such as the anti-seizure drug carbamazepine, is clinically discouraged as it may dramatically blunt Sunharbo's preventative potency. The therapy is similarly not recommended for individuals living with moderate to severe hepatic impairment. Make sure to double-check the physical label to confirm this information regarding proper usages and contraindications.



